AppLovin shares pop on earnings beat as it announces sale of mobile gaming business

AppLovin shares pop on earnings beat as it announces sale of mobile gaming business


Thomas Fuller | SOPA Images | Lightrocket | Getty Images


AppLovin shares soared as high as 15% in extended trading after the company reported earnings and revenue that beat expectations and announced the sale of its mobile gaming business.

Here’s how the company did compared to LSEG consensus estimates:

  • Earnings: $1.67 per share vs $1.45 per share expected
  • Revenue: $1.48 billion vs $1.38 billion expected

AppLovin also agreed on Wednesday to sell its mobile gaming business to Tripledot Studios in a deal worth $400 million in cash considerations. The advertising tech company will also obtain  a roughly 20% ownership stake in Tripledot Studios, which makes mobile games like Sudoko Friends, Puzzletime and Solitaire Classic.”

The deal is expected to close in the second quarter of 2025.

AppLovin said second-quarter sales should come in the range of $1.2 billion to $1.22 billion, trailing analysts expectations of $1.38 billion.

The company reported first-quarter net income of $576 million, or $1.67 per share, up from $234 million, or 67 cents per share, in the same quarter of 2024.

AppLovin total costs and expenses for the first quarter came in at $820.55 million, representing a 14% increase from the previous year during the same quarter.

The ad-tech firm said in February that it had signed a term sheet to sell its apps business for “total estimated consideration” of $900 million, which included $500 million in cash.

AppLovin’s business has been split between advertising and apps, which is primarily made up of game studios that the company has acquired over the years. With the historic growth in its advertising unit, due to rapid advancements in artificial intelligence, the apps business had become much less important.

The company logged $1.16 billion in first-quarter advertising sales, up from the $678 million it recorded a year ago during the same period.

Sales of the company’s apps-related business for the quarter came in at $325 million, which was a 14% decline from the prior year.

AppLovin’s stock surged over 700% in 2024 and was the top performer in the sector, thanks to the AI boom and growth in online advertising.

The company’s shares dropped 12% in February after short sellers published reports casting doubt on its AI-powered AXON advertising software.

WATCH: Activist Robby Starbuck on why he’s suing Meta for defamation

Activist Robby Starbuck on why he's suing Meta for defamation



Source

Supreme Court allows Trump to withhold  billion in foreign aid funding
World

Supreme Court allows Trump to withhold $4 billion in foreign aid funding

A person walks past the U.S. Supreme Court in Washington, D.C., U.S., April 21, 2025. Kevin Lamarque | Reuters The Supreme Court on Friday handed another win to the Trump administration by allowing it to withhold $4 billion in spending on foreign aid that was appropriated by Congress. A federal judge had previously ruled that the administration would have […]

Read More
Chinese stocks are on fire this year, drawing big interest from foreign and domestic investors
World

Chinese stocks are on fire this year, drawing big interest from foreign and domestic investors

When Hou Yujie isn’t convincing customers to rent traditional Chinese clothing for photos at the country’s famous Forbidden City, she and her friends are checking stocks. Hou recently put 10% of her money in the market. In just a few days, she earned one month’s salary — and she’s thrilled.  “Interest rates for bank deposits […]

Read More
U.S. pharma tariffs spare India’s generic drugmakers — but leave investors jittery
World

U.S. pharma tariffs spare India’s generic drugmakers — but leave investors jittery

MUMBAI, INDIA – MARCH 3: A technician works at a Cipla laboratory March 3, 2002 in Vikhrohi, Mumbai, India. Jean-marc Giboux | 3rd Party – Misc | Getty Images Stocks of leading Indian drugmakers fell on Friday, even though the 100% U.S. tariffs on branded and patented drug imports are unlikely to affect these companies. […]

Read More